vTv Therapeutics (VTVT) Stock Overview
A late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
VTVT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
vTv Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.75 |
| 52 Week High | US$44.00 |
| 52 Week Low | US$14.00 |
| Beta | 0.40 |
| 1 Month Change | 0.14% |
| 3 Month Change | 3.26% |
| 1 Year Change | 86.55% |
| 3 Year Change | 24.12% |
| 5 Year Change | -62.80% |
| Change since IPO | -91.56% |
Recent News & Updates
We Think vTv Therapeutics (NASDAQ:VTVT) Can Easily Afford To Drive Business Growth
Apr 06
Here's Why We're Not Too Worried About vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation
Dec 02Recent updates
We Think vTv Therapeutics (NASDAQ:VTVT) Can Easily Afford To Drive Business Growth
Apr 06Here's Why We're Not Too Worried About vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation
Dec 02Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?
Jul 11We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully
Feb 02Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation
Aug 24Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?
May 11vTv Therapeutics GAAP EPS of -$0.04
Aug 16vTv stock soars 18% on $10M equity investment by CinRx Pharma
Jul 25We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully
Aug 17Shareholder Returns
| VTVT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | 2.0% | 3.4% |
| 1Y | 86.5% | 43.3% | 34.6% |
Return vs Industry: VTVT exceeded the US Biotechs industry which returned 43.3% over the past year.
Return vs Market: VTVT exceeded the US Market which returned 34.6% over the past year.
Price Volatility
| VTVT volatility | |
|---|---|
| VTVT Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: VTVT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VTVT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 26 | Paul Sekhri | vtvtherapeutics.com |
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases.
vTv Therapeutics Inc. Fundamentals Summary
| VTVT fundamental statistics | |
|---|---|
| Market cap | US$468.09m |
| Earnings (TTM) | -US$26.97m |
| Revenue (TTM) | n/a |
Is VTVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTVT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$17.86m |
| Gross Profit | -US$17.86m |
| Other Expenses | US$9.11m |
| Earnings | -US$26.97m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VTVT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/16 22:47 |
| End of Day Share Price | 2026/04/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
vTv Therapeutics Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Douglas Buchanan | Brean Capital Historical (Janney Montgomery) |
| Kambiz Yazdi | BTIG |